Lv7
5010 积分 2022-04-26 加入
Usefulness of the Human Tumor Colony Forming Assay for New Drug Development
6天前
已完结
In Vitro Evidence of Synergistically Enhanced Efficacy of Axitinib When Combined with Asciminib in T315I Mutated Chronic Myeloid Leukemia
8天前
已关闭
Abstract 1775: The profiling of MTAP homozygous deletion (MTAPhd) in a Chinese pan-cancer cohort
1个月前
已关闭
501LBA LBA Orals: Phase 1 expansion results of IDE397, a first-in-class, oral, MAT2A inhibitor (MAT2Ai) in MTAP deleted(del) non-small cell lung cancer (NSCLC) and urothelial cancer (UC)
1个月前
已关闭
First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration
1个月前
已完结
CELL LINES USED IN PROSTATE CANCER RESEARCH: A COMPENDIUM OF OLD AND NEW LINES—PART 2
2个月前
已完结
Structure-Based Design and Optimization of Methionine Adenosyltransferase 2A (MAT2A) Inhibitors with High Selectivity, Brain Penetration, and In Vivo Efficacy
2个月前
已完结
Overcoming asciminib resistance by targeting compound BCR::ABL1 mutations in chronic myeloid leukemia
2个月前
已关闭
Asciminib: the tyrosine kinase inhibitor with a unique mechanism of action
2个月前
已完结
LPA81: Discovery of an Exceptionally Potent Protac Degrading Native and Mutant BCR-ABL1 Oncoprotein in CML
2个月前
已关闭
皖公网安备34019202002308
